Black Diamond Therapeutics, Inc. - Common Stock (BDTX)

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class
Equity / Common Stock
Shares outstanding
56,078,244
Total 13F shares
24,796,493
Share change
-4,275,027
Total reported value
$302,261,425
Put/Call ratio
178%
Price per share
$12.19
Number of holders
96
Value change
-$88,608,277
Number of buys
62
Number of sells
46

Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q2 2021

As of 30 Jun 2021, Black Diamond Therapeutics, Inc. - Common Stock (BDTX) was held by 96 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 24,796,493 shares. The largest 10 holders included Bellevue Group AG, NEA Management Company, LLC, RA CAPITAL MANAGEMENT, L.P., BlackRock Inc., BOXER CAPITAL, LLC, Artal Group S.A., VANGUARD GROUP INC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), FEDERATED HERMES, INC., and Capital World Investors. This page lists 97 institutional shareholders reporting positions in this security for the Q2 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.